Clinical stage diagnostics company AccuStem Sciences has acquired the licence for the microRNA Signature Classifier (MSC) test, which aims to aid in lung cancer screening.
The acquisition involves the transfer of all intellectual property rights related to the MSC test, with AccuStem issuing 3.75 million common shares as full payment to specific secured creditors, as well as interest holders.
These shares are subject to resale restrictions for 13 months from the closing date of the acquisition.
The blood-based test, created by researchers at Istituto Nazionale Tumori, Italy, claims to assess 24 microRNAs to enhance the diagnostic ability of low-dose computed tomography (LDCT) in individuals with pulmonary nodules.
Leveraging MSC with LDCT aids clinicians in stratifying and managing the nodules of the lung, stated the company.
The inventors of the MSC test, namely Ugo Pastorino; Gabriella Sozzi; and Mattia Boeri are set to continue their association with AccuStem, offering research and historical data related to the test.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccuStem is focused on improving patient outcomes and quality of life in cancer care. It aims to provide molecular testing that fulfils clinical needs across the spectrum of cancer care, from screening to treatment and monitoring.
AccuStem Sciences CEO Wendy Blosser said: “We are excited to obtain the rights to a novel test like MSC that could meaningfully benefit the millions of patients diagnosed with lung nodules each year.
“We believe the test will provide more definitive diagnoses and peace of mind for patients beyond LDCT screening alone, with the added benefit of saving costs to the healthcare system.”
In July 2023, the company signed an agreement with EmeritusDX to co-manage research and development, as well as scientific operations for AccuStem’s product range.
